Ten research investigations

Original notes reproduced from the merged research dossier without converting preliminary interpretations into approved medical recommendations. Source links are provided above. Other limitations in the full text still apply.

**Question:** Does “more fiber” mean the same clinical response across soluble and insoluble products?  
**Primary:** Bijkerk et al., BMJ 2009, [PMID 19713235](https://pubmed.ncbi.nlm.nih.gov/19713235/), [DOI 10.1136/bmj.b3154](https://doi.org/10.1136/bmj.b3154). Randomized, placebo-controlled primary-care trial with **275 adults** with IBS, 12 weeks; psyllium (n=85), bran (n=97), rice-flour placebo (n=93).  
**Prespecified endpoint:** Adequate symptom relief during at least two weeks in the past month. **Psyllium versus placebo**: month 1 **57% vs 35%**, RR 1.60 (95% CI 1.13–2.26); month 2 **59% vs 41%**, RR 1.44 (1.02–2.06). At month 3, psyllium symptom-severity score improved more than placebo, but adequate-relief differences were not robustly significant by conservative missing-data imputation. **Quality of life did not significantly differ** among groups. Bran's apparent month-3 improvement was not significant in the worst-case analysis, and early symptom worsening contributed to bran dropouts.  
**Boundary:** Selected adults in primary care, not all IBS subtypes or all isolated fibers. The comparison is for IBS symptom relief, **not LDL lowering** (addressed under DE10-09), clinical nutrition advice, or any fiber product with an unmatched viscosity/form. Attrition was material across all arms.  
**Research disposition:** P1 article/claim audit: retain a positive near-term placebo-adjusted signal, the follow-up/attrition caveat, and a null quality-of-life result together.

Original notes reproduced from the merged research dossier without converting preliminary interpretations into approved medical recommendations. Source links are provided above. Other limitations in the full text still apply.

**Adult source:** Grant et al., 2009, [PMID 19581567](https://pubmed.ncbi.nlm.nih.gov/19581567/). Placebo-controlled, double-blind **50-adult**, 12-week randomized trial. **56%** on NAC were rated much/very much improved versus **16%** placebo (P=.003); symptom-scale comparisons also favored NAC; a detectable separation was reported only after approximately nine weeks.  
**Pediatric source:** Bloch et al., 2013, [PMID 23452680](https://pubmed.ncbi.nlm.nih.gov/23452680/), [DOI 10.1016/j.jaac.2012.12.020](https://doi.org/10.1016/j.jaac.2012.12.020). Double-blind, randomized 12-week **39-child/adolescent** add-on trial, ages 8–17. **No statistically significant difference** on primary or secondary measures; clinician-rated responders **25% NAC vs 21% placebo**. Improvement over time in both arms is not treatment superiority.  
**Interpretation:** These are **two independently randomized populations**, not two estimates from the same trial. The pediatric result does not prove absence of any possible biological action in children, and the adult signal does not justify pediatric extrapolation or over-the-counter self-treatment. The pediatric authors emphasized behavioral therapy as a clinically supported approach; safety/interaction claims require separate review.  
**Research disposition:** P0 population firewall. The adult PMID already appears in site NAC content; **reuse**, not a novel-citation claim. Do not conflate NAC bioavailability evidence (a separate research question) with evidence for psychiatric outcomes.

Original notes reproduced from the merged research dossier without converting preliminary interpretations into approved medical recommendations. Source links are provided above. Other limitations in the full text still apply.

**Primary:** Okereke et al., JAMA 2020, [PMID 32749491](https://pubmed.ncbi.nlm.nih.gov/32749491/), [DOI 10.1001/jama.2020.10224](https://doi.org/10.1001/jama.2020.10224). Randomized clinical study of **18,353** older adults followed for median **5.3 years**.  
**Results:** Incident/recurrent depression or clinically relevant symptoms **609 events with vitamin D3 vs 625 with placebo**; HR **0.97** (95% CI 0.87–1.09), P=.62. Change in PHQ-8 mood score also **null** (mean between-arm difference 0.01 points, 95% CI −0.04 to 0.05).  
**Boundary:** Population-level prevention in adults aged around 67 on average, **not a trial of treating diagnosed vitamin D deficiency, severe depressive disorder or another specific deficiency-linked syndrome**. The broad “vitamin D boosts mood/prevents depression” proposition is not supported here. Do not count VITAL-DEP and other VITAL ancillary papers as wholly independent randomized cohorts when discussing aggregate independence.  
**Research disposition:** P1 outcome/population correction candidate; no clinical supplement advice.

Original notes reproduced from the merged research dossier without converting preliminary interpretations into approved medical recommendations. Source links are provided above. Other limitations in the full text still apply.

**Primary:** Wang et al., Ann Intern Med 2020, [PMID 32926799](https://pubmed.ncbi.nlm.nih.gov/32926799/), [DOI 10.7326/M20-0990](https://doi.org/10.7326/M20-0990). Single-center, 12-week double-blind placebo RCT of **70** people with symptomatic knee OA and imaging-defined effusion-synovitis (extract n=36, placebo n=34). **Two primary outcomes:** knee pain VAS change and MRI effusion-synovitis volume.  
**Results:** Extract versus placebo: VAS pain difference **−9.1 mm** (95% CI −17.8 to −0.4; P=.039), positive; **MRI effusion-synovitis volume difference 3.2 mL** (95% CI −0.3 to 6.8), **null**. Secondary WOMAC pain improved, but MRI cartilage-composition measure did not. Short-term adverse events did not statistically differ, which **cannot certify long-term liver safety**.  
**Boundary:** Specific extract, small sample, selected OA phenotype and 12-week outcomes. Symptom relief ≠ cartilage regeneration, MRI synovitis resolution, disease modification, or all turmeric extracts. Separately assessed liver-injury evidence must remain visible when safety copy is later reviewed; the trial's low power and duration cannot exclude rare injury. Funding included a remedies company; check financial disclosures at full-text review.  
**Research disposition:** P0 overselling/benefit-risk and formulation-specific check.

Original notes reproduced from the merged research dossier without converting preliminary interpretations into approved medical recommendations. Source links are provided above. Other limitations in the full text still apply.

**Primary:** Heymsfield et al., JAMA 1998, [PMID 9820262](https://pubmed.ncbi.nlm.nih.gov/9820262/), [DOI 10.1001/jama.280.18.1596](https://doi.org/10.1001/jama.280.18.1596). Twelve-week randomized, double-blind, placebo-controlled outpatient weight-management trial in **135** overweight adults (66 active, 69 placebo), with dietary measures in both arms.  
**Results:** **3.2 kg vs 4.1 kg** mean loss, active versus placebo; between-group difference **not significant** (P=.14). Completion was **42/66 active** versus **42/69 placebo**; both arms improved from baseline. Do not reframe before/after decline as supplement-attributable slimming.  
**Boundary:** A specific hydroxycitric-acid product and studied dietary setting, not proof that *no* imaginable formulation works; also not a contemporary assay or full modern safety review. This outcome strongly challenges a confident generalized “Garcinia burns fat” advertisement.  
**Research disposition:** P0 marketing accuracy candidate. **PMID already appears** in repository claim/data/export files; do not count as a newly discovered source.

Original notes reproduced from the merged research dossier without converting preliminary interpretations into approved medical recommendations. Source links are provided above. Other limitations in the full text still apply.

**Primary:** McKay et al., J Nutr 2010, [PMID 20018807](https://pubmed.ncbi.nlm.nih.gov/20018807/), [DOI 10.3945/jn.109.115097](https://doi.org/10.3945/jn.109.115097). Six-week double-blind placebo-controlled study of **65** prehypertensive or mildly hypertensive adults, ages 30–70, **not using antihypertensive medication**. Brewed hibiscus tea versus placebo beverage.  
**Results:** Systolic BP change **−7.2 ± 11.4 mmHg hibiscus vs −1.3 ± 10.0 placebo**, P=.030; diastolic **−3.1 vs −0.5**, P=.160 (**null**), and mean arterial pressure P=.054 (borderline, not a conventional positive). Baseline systolic BP moderated response in analysis.  
**Boundary:** Tea tisane, not isolated anthocyanin capsules or all hibiscus products; six-week physiological endpoint is not demonstrated stroke, heart-attack or mortality reduction, and the sample excludes users of BP drugs. Original work included industry support: note before consumer summary.  
**Research disposition:** P1; separate statistically supported systolic from null diastolic and unmeasured hard outcomes.

Original notes reproduced from the merged research dossier without converting preliminary interpretations into approved medical recommendations. Source links are provided above. Other limitations in the full text still apply.

**Primary:** Akhondzadeh et al., Phytother Res 2005, [PMID 15852492](https://pubmed.ncbi.nlm.nih.gov/15852492/), [DOI 10.1002/ptr.1647](https://doi.org/10.1002/ptr.1647). **40 adult outpatients** with mild-to-moderate major depressive disorder, six-week double-blind single-center placebo RCT studying *Crocus sativus* stigmas.  
**Results:** Hamilton depression scale outcome favored saffron at week 6 (F=18.89, P<.001); reported adverse-effect counts did not significantly differ in this small trial.  
**Boundary:** Small, brief and single-center. This does **not** demonstrate effectiveness for severe disease, long-term relapse prevention, equivalence to prescribed antidepressants, interaction freedom, or safety of abruptly replacing treatment. Saffron extract identity and trial-level risk of bias must be checked before copy is promoted.  
**Newer contrasting primary trial:** Amadieu et al., *American Journal of Clinical Nutrition* 2025 (published online October 3, 2025), [PMID 41047129](https://pubmed.ncbi.nlm.nih.gov/41047129/), [DOI 10.1016/j.ajcnut.2025.09.050](https://doi.org/10.1016/j.ajcnut.2025.09.050). Double-blind placebo-controlled six-week RCT of **51 otherwise healthy adults with subclinical depressive symptoms**. The prespecified primary composite of depressive, anxiety and fatigue scores was **not significantly different** from placebo; individual symptom outcomes were also null. Authors described a possible secondary self-perceived mental-health signal but requested replication. The published abstract's description of the secondary group means warrants full-text direction verification; **do not promote its precise secondary means or direction before that check**. The null subclinical result does not invalidate the earlier clinical-depression result, and the earlier result cannot substitute for a subclinical population. This 2025 PMID already appears in prior repository enrichment-wave indices and must be **reused**, not counted as a novel canonical source.  
**Research disposition:** P0 false-substitution/interaction risk and outcome/population review. The 2005 PMID **already occurs** in prior repository enrichment selections/register; both saffron records need canonical source-key reconciliation.

Original notes reproduced from the merged research dossier without converting preliminary interpretations into approved medical recommendations. Source links are provided above. Other limitations in the full text still apply.

**Primary:** Sándor et al., Neurology 2005, [PMID 15728298](https://pubmed.ncbi.nlm.nih.gov/15728298/), [DOI 10.1212/01.WNL.0000151975.03598.ED](https://doi.org/10.1212/01.WNL.0000151975.03598.ED). **42 adults** with migraine in a double-blind placebo RCT; study reported outcome at month 3.  
**Results:** A ≥50% attack-frequency response was **47.6% CoQ10 vs 14.4% placebo**; reductions in attack frequency, headache days and nausea days favored active treatment in the third month. Small sample and multiple measured symptoms prevent certainty about the true population effect size.  
**Boundary:** Migraine prophylaxis differs from chronic migraine treatment and from the negative statin-myalgia evidence in DE11. A response in one condition cannot rescue a null in another or guarantee universal pain relief. Trial exposure is **not dosing advice**.  
**Research disposition:** P1 contrast/indication-specific update candidate; assess modern independent replications before confidence-tier change.

Original notes reproduced from the merged research dossier without converting preliminary interpretations into approved medical recommendations. Source links are provided above. Other limitations in the full text still apply.

**Primary:** Kalliomäki et al., Lancet 2001, [PMID 11297958](https://pubmed.ncbi.nlm.nih.gov/11297958/), [DOI 10.1016/S0140-6736(00)04259-8](https://doi.org/10.1016/S0140-6736(00)04259-8). Double-blind RCT among pregnancies with familial atopic-risk history, giving *Lactobacillus rhamnosus* GG around birth and to infants through six months.  
**Results:** At age two years, atopic eczema in **15/64 (23%) probiotic vs 31/68 (46%) placebo**, RR **0.51** (95% CI 0.32–0.84), positive within this trial. **Follow-up publications of these children must not be counted as independent replications.**  
**Boundary:** Selected high-risk families, one strain and prenatal/postnatal regimen; not a claim that every multi-strain probiotic prevents eczema, asthma or food allergy. Infant and pregnancy exposure and infection risk require clinician-level evaluation and replication review; **no parent-facing starting instructions from this dossier**.  
**Research disposition:** P0 high-risk population/strain identity review. Do not pool with the older inpatient AAD-negative trial in DE13 as if the same endpoint.

Original notes reproduced from the merged research dossier without converting preliminary interpretations into approved medical recommendations. Source links are provided above. Other limitations in the full text still apply.

**Primary:** Stranges et al., Ann Intern Med 2007, [PMID 17620655](https://pubmed.ncbi.nlm.nih.gov/17620655/), [DOI 10.7326/0003-4819-147-4-200708210-00175](https://doi.org/10.7326/0003-4819-147-4-200708210-00175). **Secondary analysis** of a randomized, double-blind, placebo-controlled cancer-prevention trial; **1,202** nondiabetic adults, mean follow-up **7.7 years**.  
**Results:** New diabetes cases **58 selenium vs 39 placebo**; incidence **12.6 versus 8.4 per 1,000 person-years**; HR **1.55** (95% CI 1.03–2.33). The study does **not** show diabetes prevention; it raises a possible harm signal, notably in a population mostly older and white.  
**Critical evidence hierarchy:** Diabetes was **not** the parent's primary endpoint; diagnostic status was self-reported, although most cases were validated. Baseline selenium and tested exposure may differ from populations with deficiency and from food selenium. Avoid portraying a secondary result as a preplanned diabetes-prevention RCT, or claiming a universal incidence/harm threshold. The DE11 SELECT trial concerned **prostate cancer**, a separate disease endpoint.  
**Research disposition:** P0 safety/marketing claim audit with source-role and endpoint-class flags.

## Repository deduplication and scientific integrity receipt

- **Ten** distinct investigation questions; **12** distinct PMID citation identities; **12** distinct randomized clinical study cohorts (including two separate NAC trials). The two NAC PMIDs are **not** one trial. No companion follow-up is added or counted as a new independent cohort.
- Targeted default-branch code search found **existing occurrences** of PMID 19581567 (NAC content/guide), **9820262** (Garcinia claims/data/export), **15852492** (saffron prior enrichment/register), and **41047129** (2025 saffron prior enrichment indices). These are **known reuse**, not novelty. Other PMIDs returned no indexed matches in that limited search, which **does not establish absence from immutable ledgers, branch histories, queued research or full canonical metadata**.
- **Negative/null outcomes preserved**: the saffron 2025 primary mood composite; psyllium quality-of-life and robust month-3 adequate relief; pediatric NAC; vitamin D depression risk/mood; turmeric MRI synovitis/cartilage; Garcinia placebo-adjusted weight; hibiscus diastolic; CoQ10 other indication not inferred; selenium diabetes prevention absent.
- **Source classification:** All cited records are human randomized trials, but **the selenium diabetes analysis is a secondary outcome of a cancer-prevention RCT**, not a diabetes-primary trial. No animal/in-vitro results were used to justify human clinical efficacy.
- **Provenance limitations:** Title, PMID, DOI (where listed), design and key abstract outcomes checked against source records; no full-corpus systematic search, formal RoB-2 assessment, comprehensive retraction sweep, live product assay, independent reviewer confirmation or exact canonical database admission. These missing checks are not silently marked PASSED.
- **Before downstream implementation:** (1) inspect current public claims and indications, (2) canonical PMID+DOI dedupe and source-role mapping, (3) resolve species/part/formulation/route, patient population, endpoint, sample and risk of bias, (4) retain null and safety findings, (5) seek independent owner-authorized scientific review, (6) test PR and safety/indexability gates, (7) inspect deployed text post-publication.
- **No ROI attribution:** This is research inventory only: **0 asserted new published pages, 0 confirmed novel canonical admissions, 0 evidenced additional citations/traffic/revenue**.